CAMP4 Therapeutics reports preclinical data showing CMP-002 improves seizure threshold in SYNGAP1 model

Camp4 Therapeutics Corp

CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.
Data presented at TIDES conference on May 14, 2026; builds on prior motor/behavioral benefit evidence.
Company plans to advance CMP-002 into a Phase 1/2 clinical trial in SYNGAP1-related disorder in H2 2026.
Lead candidate CMP-002 is an antisense oligonucleotide targeting regulatory RNA to upregulate SYNGAP1 protein.
Study used PTZ-induced seizure model; CMP-002 conferred resistance to tonic-clonic seizures and reduced severity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.